SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bacil Pharma - Quaterly Results

21 Jan 2025 Evaluate
The revenue slipped marginally during the December 2024 quarter. A decline of about Rs. 0.00 millions was observed as compared to Rs. 0.00 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2024 is Rs. -0.62 millions as compared to Net Loss of Rs. -0.24 millions of corresponding quarter ended December 2023 Operating profit Margin for the quarter ended December 2024 further decreased to -0.62% as compared to -0.23% of corresponding quarter ended December 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Income 0.02 0.33 -93.94 5.73 1.10 420.91 1.31 1.15 13.91
PBIDT -0.62 -0.23 169.57 3.93 -0.16 -2556.25 -0.57 -0.99 -42.42
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT -0.62 -0.23 169.57 3.93 -0.16 -2556.25 -0.57 -0.99 -42.42
Depreciation 0.00 0.01 0.00 0.00 0.03 -100.00 0.02 0.03 -33.33
PBT -0.62 -0.24 158.33 3.93 -0.19 -2168.42 -0.59 -1.02 -42.16
TAX 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00
PAT -0.62 -0.24 158.33 3.90 -0.19 -2152.63 -0.59 -1.02 -42.16
Equity 58.90 58.90 0.00 58.90 58.90 0.00 58.90 58.90 0.00
PBIDTM(%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Bacil Pharma Share Price

54.99 -0.69 (-1.24%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.75
Dr. Reddys Lab 1270.95
Cipla 1333.55
Zydus Lifesciences 911.85
Lupin 2343.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×